Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6 months from diagnosis 1 . Numerous phase 3 trials of agents effective in other malignancies have failed to benefit unselected PDA populations, although patients do occasionally respond. Studies in other solid tumors have shown that heterogeneity in response is determined, in part, by molecular differences between tumors. Furthermore, treatment outcomes are improved by targeting drugs to tumor subtypes in which they are selectively effective, with breast 2 and lung 3 cancers providing recent examples. Identification of PDA molecular subtypes has been frustrated by a paucity of tumor specimens available for study. We have overcome this problem by combined analysis of transcriptional profiles of primary PDA samples from several studies, along with human and mouse PDA cell lines. We define three PDA subtypes: classical, quasimesenchymal and exocrine-like, and we present evidence for clinical outcome and therapeutic response differences between them. We further define gene signatures for these subtypes that may have utility in stratifying patients for treatment and present preclinical model systems that may be used to identify new subtype specific therapies.
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease. Overall survival is typically 6 months from diagnosis 1 . Numerous phase 3 trials of agents effective in other malignancies have failed to benefit unselected PDA populations, although patients do occasionally respond. Studies in other solid tumors have shown that heterogeneity in response is determined, in part, by molecular differences between tumors. Furthermore, treatment outcomes are improved by targeting drugs to tumor subtypes in which they are selectively effective, with breast 2 and lung 3 cancers providing recent examples. Identification of PDA molecular subtypes has been frustrated by a paucity of tumor specimens available for study. We have overcome this problem by combined analysis of transcriptional profiles of primary PDA samples from several studies, along with human and mouse PDA cell lines. We define three PDA subtypes: classical, quasimesenchymal and exocrine-like, and we present evidence for clinical outcome and therapeutic response differences between them. We further define gene signatures for these subtypes that may have utility in stratifying patients for treatment and present preclinical model systems that may be used to identify new subtype specific therapies.
Global gene expression analysis has proved useful for subtype identification in many human tumor types 4 . We approached PDA subtype identification by first identifying intrinsically variable (s.d. > 0.8) genes in two gene expression microarray data sets from resected PDA. We generated one data set with microdissected PDA material (UCSF tumors, n = 27) from clinical samples for which information on survival duration was available, and the second was previously published (GSE15471) 5 . To increase power, we merged these two data sets with the distance-weighted discrimination (DWD) method 6, 7 and included intrinsically variable genes common to both studies. We then performed non-negative matrix factorization (NMF) analysis with consensus clustering 8 to identify subtypes of the disease. This analysis supported up to three subtypes (cophenetic coefficient > 0.99; Supplementary Figs. 1 and 2a and Supplementary Tables 1-3) . We then developed a gene signature by using subtypes defined in NMF analysis of the merged clinical data sets to supervise significance ana lysis of microarrays (SAM) analysis 9 with false discovery rate (FDR) less than 0.001. This resulted in a 62-gene signature, which we designated PDAssigner. The three PDA subtypes in the merged clinical data set and their expression of PDAssigner genes are shown in Figure 1a . We designated these subtypes as classical, quasimesenchymal (QM-PDA) and exocrine-like, on the basis of our interpretation of subtypespecific gene expression. The classical subtype had high expression of adhesion-associated and epithelial genes, and the QM-PDA subtype showed high expression of mesenchyme-associated genes. The exocrine-like subtype showed relatively high expression of tumor cell-derived digestive enzyme genes ( Fig. 1a and Supplementary  Fig. 3) , with immunohistochemical staining supporting this observation (Supplementary Fig. 3 ). Analysis of PDAssigner gene expression in three additional published PDA expression data sets of unique origin, platform or processing 10-12 also supported these three subtypes ( Supplementary Fig. 4) , indicating the robust nature of the subtype classification in early-stage PDA.
Survival after PDA resection has been associated with many factors, including stage (tumor size and nodal involvement) and grade (degree of differentiation) 13 , but no one factor has been consistently prognostic 14, 15 . We found that stratification by PDA transcriptional subtype provided useful prognostic information in one PDA data set (UCSF) for which clinical annotation was available. Specifically, individuals with classical subtype tumors fared better than individuals with QM-PDA subtype tumors after resection (P = 0.038, log rank, Fig. 1b) . In this same data set, stage and grade were not significantly related (P > 0.99) and stage was not significantly associated with subtype (P = 0.40), whereas grade was (P = 0.041) (univariate analyses). In a multivariate Cox regression model including stage and subtype, subtype was an indepen dent predictor of overall survival (P = 0.024), indicating that PDA subtype independently contributed prognostic information to pathological staging in PDA. Associations of PDA subtype with other clinical variables are summarized in Supplementary Table 4 . This analysis supports the use of subtypes (as defined with PDAssigner) as an independent prognostic indicator in resected PDA.
Further validation of PDA subtypes and preclinical identification of subtype-specific therapeutic agents would be facilitated by the availability of laboratory models of the subtypes. Therefore, we asked whether the PDA subtypes were represented in a collection of 19 human and 15 mouse PDA cell lines. The 19 human PDA cell lines were selected from publicly available PDA lines, whereas the 15 mouse lines were derived by us from genetically engineered Trp53 Lox/+ (lacking the tumor suppressor p53) and Cdkn2a Lox/+ (lacking cyclin-dependent kinase inhibitor 2A) models of PDA 16 . The analyses of the human and mouse PDA cell lines using the 62 PDAssigner genes are shown (Fig. 1c, 6 ). These cell line collections contain representatives of the classical and QM-PDA subtypes, but not the exocrine-like subtype. The absence of the exocrine-like subtype in the cell line collection raises the possibility that this subtype is an artifact of contaminating normal pancreas tissue adjacent to tumor. However, the UCSF samples were prepared by microdissection to enrich for PDA cancer cells, thereby minimizing contaminating tumor-associated stroma and adjacent normal exocrine pancreas. This data set includes the exocrine-like subtype, which argues that it is a bona fide PDA subtype. Thus, we conclude that the cell line collections model two of the PDA subtypes, thereby enabling exploration of biological differences between these two PDA subtypes a b
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Two genes associated with PDA subtypes, GATA binding protein-6 (GATA6) and v-ki-ras2 kirsten rat sarcoma viral oncogene homolog (KRAS), both variable genes in our UCSF PDA data set (Supplementary Table 1a) , have been implicated in both aspects of normal development and cancer pathophysiology in published studies. GATA-family transcription factors are associated with tissuespecific differentiation and have been shown to be subtype specific markers in other cancers. For example, GATA3 is required for luminal differentiation in the breast 17 , and high GATA3 expression characterizes luminal subtype breast cancers 18 . Likewise, GATA6 is essential for pancreatic development 19 and has been implicated in PDA 20, 21 . GATA6 is highly expressed in most classical subtype tumors and cell lines, and its expression is comparatively low in the QM-PDA cell lines and tumors. Additionally, a previously published gene signature associated with GATA6 overexpression 20 is enriched in the classical subtype (Supplementary Fig. 5 ). Seeking to establish a possible functional role underlying the observed differences in GATA6 expression, we assessed the impact of RNAi knockdown of GATA6 on colony formation in soft agar in the classical and QM-PDA cell lines. GATA6 depletion impaired anchorage-independent growth in classical PDA cell lines, but not in QM-PDA cell lines (Fig. 2) , consistent with a functional, subtype-specific role for this transcription factor in the classical PDA subtype.
Recent work in the mouse has shown that PDA can arise from a variety of precursor cells by activating KRAS in distinct cellular compartments of the pancreas 22 . Others have found that cancer cell lines harboring mutant KRAS differ in their dependence on KRAS 23 . These findings imply plasticity in either reliance on KRAS signaling or a cell-type specific role for mutant KRAS in cells of different origin or lineages in PDA, or both. They further suggested to us that despite the presence of KRAS mutations in most PDAs, KRAS dependence might differ by PDA subtype. We found KRAS mRNA levels elevated in classical subtype PDAs relative to the other subtypes (Supplementary Fig. 6 ). We explored the relationship between KRAS dependence and subtype by using RNAi to probe KRAS-mutant human PDA cell lines for dependence on KRAS. Classical PDA lines proved to be relatively more dependent on KRAS than QM-PDA lines (Fig. 3) . Further, a previously reported signature of KRAS addiction 23 was enriched in the classical subtype (Supplementary Fig. 7) . These results suggest that KRAS-directed therapy, although not yet a clinical reality, might be best deployed in classical PDA. Mouse models capable of sequentially activating and then deleting mutant KRAS would further these observations to genetically define the respective roles mutant KRAS has in both the initiation and the ongoing maintenance of PDA.
We tested the possibility that PDA subtypes with different biological characteristics might have subtype-specific drug responses by measuring responses to gemcitabine and erlotinib (the backbone of current treatment regimens 24 ) in human PDA cell lines of known subtype. QM-PDA subtype lines were, on average, more sensitive to gemcitabine than the classical subtype (Fig. 4) . Conversely, erlotinib was more effective in classical subtype cell lines. This suggests that KRAS mutation status is an imperfect predictor of sensitivity to epidermal growth factor receptor-targeted therapy in PDA, an observation consistent with findings in non-small-cell lung 25 and colorectal cancers 26 , and implies that cancer cells dependent on mutant KRAS still employ the epidermal growth factor receptor to some extent. These results further establish phenotypic differences between the classical and QM-PDA subtypes and suggest that these and perhaps additional drugs will show subtype specificity in PDA, a distinction that could be exploited in clinical trial sensitivity enrichment schemes. More immediately, these results indicate that gemcitabine and erlotinib are preferentially active in different PDA subtypes, so that the current practice of combining them may increase toxicity without increasing efficacy for many patients. Combining agents with similar subtype specificity might be considered instead.
In summary, our data support the existence of three intrinsic subtypes of PDA that progress at different rates clinically and may respond differently to selected therapies. The validity of these subtypes is supported by analysis of multiple primary clinical data sets as well as of PDA cell lines both from human tumors and from mouse models engineered with the hallmark genetic lesions of human PDA. Knowledge of these subtypes may motivate investigation of associations between clinico-pathologic variables and these subtypes by collaborative consortia examining the molecular diversity of PDA 27 . The markers that define these subtypes may have prognostic utility in risk-adapted surgical approaches 28 or predictive utility in sensitivity enrichment schemes. The use of subtyped human and mouse PDA preclinical models promises to accelerate identification of subtype specific functional and regulatory processes that can be exploited to therapeutic benefit. In turn, such assay systems could be used to screen therapeutic approaches, empirically or based on mechanism, to identify those that are potent against PDA, either in a specific subtype that would then be used to personalize treatment 29 , or spanning the subtypes with possible therapeutic generality.
Accession codes. All array data are available at Gene Expression Omnibus (GEO) with accession code GSE17891.
MeThODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. Detailed protocols are available on the Nature Protocol Exchange at http://www. nature.com/protocolexchange/protocols/2053/publications/821. 6 . We column-normalized samples to N(0,1) and row normalized (probe or gene) each data set by median centering. We merged the processed data sets with DWD and median-centered the rows.
Non-negative matrix factorization and significance analysis of microarrays analysis. We analyzed the merged data sets by consensus clustering-based NMF 8 to identify stable subtypes using R code from GenePattern 30 . See Supplementary Methods for details regarding the interpretation of subtypes derived from consensus-based NMF clustering. We identified PDAssigner genes by three-class SAM analysis based on classes identified from NMF analysis using the Bioconductor 31 package, Siggenes, and generated heat maps of samples by PDAssigner genes using Cluster software 32 . For cell line classification, we merged the cell line data sets with core PDA clinical data sets after selection of the 62 PDAssigner genes from each data set followed by DWD based merging. We visualized data sets with the Hierarchical Clustering Viewer from GenePattern 30 .
Clinical outcome analysis. We calculated overall survival in days from the time of PDA resection until date of death as defined by the State of California Death Registry and clinical records. We used the log-rank test for univariate associations with survival or the Cox proportional hazards model for multivariate modeling of survival. We applied Fisher's exact test to investigate the relationships among subtype, stage and grade. We used the R language for all analyses. We drew the survival curve using web-based GenePattern 30 .
Drug sensitivity. We plated 2.5 × 10 3 cells per well on day 0, treated with erlotinib or gemcitabine in nine fivefold serial dilutions on day 1 and estimated cell number using Cell Titer Glow assay (Promega) on day 4. IC 50 was calculated with the Calcusyn program (Biosoft).
RNA interference.
We obtained validated pLKO-based shRNA vectors shKRAS#5 33 from B.R. Stockwell and shGATA6#5 and shLuc 34 from R. Adam. We packaged lentiviruses, transduced cells and then selected in puromycin for 48 h. For shKRAS proliferation experiments, we plated 2.5 × 10 3 transduced cells per well on day 0 in 96-well plates, then counted one plate on day 1 and the other plate on day 4. We plotted averaged ratios (shKRAS/shLuc) of relative growth (day 4/day 1) for each cell line. We confirmed protein knockdown by western blotting with the Odyssey system, with 10 µg per lane of total protein and the c19 KRas-specific antibody (Santa Cruz), normalized to total actin (I-19, Santa Cruz) and compared to pLKOshLuc-KRas levels. For GATA6 knockdown experiments, after puromycin selection, we trypsinized and plated transduced cells in soft agar as previously described 35 .
We assessed GATA6 transcript levels on the day of plating in soft agar as previously described 34 .
Additional methods. Detailed methodology is described in the Supplementary Methods. All computational analyses performed in this work, including R based computer code, is described in the accompanying Nature Protocol Exchange 36 .
